|

Lung Cancer Clinical Trials in Wisconsin

60 recruiting studies across 1 city

Browse by City

Milwaukee
60 trials

All Trials in Wisconsin

Phase
Trial Phase Dist.
A Study of I-DXd in Combination With Atezolizumab With or Without Carboplatin as First-Line Induction or Maintenance in Subjects With Extensive Stage-Small Cell Lung Cancer (IDeate-Lung03)Phase 1/2<1 mi
Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection—<1 mi
Study of Olomorasib (LY3537982) in Combination With Standard of Care in Participants With Resected or Unresectable KRAS G12C-mutant Non-Small Cell Lung CancerPhase 3<1 mi
A Phase I/II Study of VLS-1488 in Subjects With Advanced CancerPhase 1/2<1 mi
Comparing Impact of Treatment Before or After Surgery in Patients With Stage II-IIIB Resectable Non-small Cell Lung CancerPhase 3<1 mi
JoLT-Ca Sublobar Resection (SR) Versus Stereotactic Ablative Radiotherapy (SAbR) for Lung CancerPhase 3<1 mi
Testing Osimertinib as a Treatment for Lung Cancers With an EGFR Exon 20 ChangePhase 2<1 mi
A Study to Investigate the Efficacy and Safety of an Infusion of IOV-4001 in Adult Participants With Unresectable or Metastatic Melanoma or Stage III or IV Non-small-cell Lung CancerPhase 1/2<1 mi
Testing the Addition of a Type of Drug Called Immunotherapy to the Usual Chemotherapy Treatment for Non-small Cell Lung Cancer, an ALCHEMIST Treatment Trial (Chemo-IO [ACCIO])Phase 3<1 mi
Comparing Combinations of Targeted Drugs for Advanced Non-Small Cell Lung Cancer That Has EGFR and MET Gene Changes (A Lung-MAP Treatment Trial)Phase 2<1 mi
Study of Zanzalintinib in Combination With Immuno-Oncology Agents in Participants With Solid TumorsPhase 1<1 mi
Adding the Immunotherapy Drug Cemiplimab to Usual Treatment for People With Advanced Non-Small Cell Lung Cancer Who Had Previous Treatment With Platinum Chemotherapy and Immunotherapy (An Expanded Lung-MAP Treatment Trial)Phase 2/3<1 mi
Targeted Treatment for Advanced Non-Small Cell Lung Cancer That Has Increased Copies of the MET Gene (An Expanded Lung-MAP Treatment Trial)Phase 2<1 mi
Prospective Non-Interventional Study Comparing Osimertinib +/- Chemotherapy for EGFR-Mutated NSCLC Patients—<1 mi
Safety, PK and Efficacy of QXL138AM in Patients With Solid Tumors and Multiple MyelomaPhase 1<1 mi
Testing Longer Duration Radiation Therapy Versus the Usual Radiation Therapy in Patients With Cancer That Has Spread to the BrainPhase 3<1 mi
Veterans Affairs Lung Cancer Surgery Or Stereotactic RadiotherapyN/A<1 mi
A Study to Evaluate the Safety and Efficacy of Gocatamig (MK-6070) and Ifinatamab Deruxtecan (I-DXd) in Participants With Relapsed/Refractory Extensive-Stage Small Cell Lung Cancer (MK-6070-002)Phase 1/2<1 mi
Testing the Addition of High Dose, Targeted Radiation to the Usual Treatment for Locally-Advanced Inoperable Non-Small Cell Lung CancerPhase 3<1 mi
A Study of Zipalertinib in Patients With Advanced Non-Small Cell Lung Cancer With Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertions or Other Uncommon Mutation.Phase 2<1 mi
A Study of PRMT5 Inhibitor BAY 3713372 in Participants With MTAP-deleted Solid TumorsPhase 1/2<1 mi
Phase III, Open-label Study of First-line Osimertinib With or Without Datopotamab Deruxtecan for EGFRm Locally Advanced or Metastatic Non-small Cell Lung CancerPhase 3<1 mi
Thoracotomy Versus Thoracoscopic Management of Pulmonary Metastases in Patients With OsteosarcomaPhase 3<1 mi
SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry—<1 mi
A Phase 1/2 Trial of TER-2013 in Patients With Solid Tumors Harboring AKT/PI3K/PTEN Pathway AlterationsPhase 1/2<1 mi
Testing if High Dose Radiation Only to the Sites of Brain Cancer Compared to Whole Brain Radiation That Avoids the Hippocampus is Better at Preventing Loss of Memory and Thinking AbilityPhase 3<1 mi
A Study of Ifinatamab Deruxtecan Versus Treatment of Physician's Choice in Subjects With Relapsed Small Cell Lung CancerPhase 3<1 mi
Osimertinib With or Without Bevacizumab as Initial Treatment for Patients With EGFR-Mutant Lung CancerPhase 3<1 mi
A Study of LY4050784 in Participants With Advanced or Metastatic Solid TumorsPhase 1<1 mi
A Study of Navlimetostat (BMS-986504) in Participants With Pre-treated Advanced or Metastatic Non-small Cell Lung Cancer (NSCLC) With Homozygous MTAP Deletion (MountainTAP-9)Phase 2<1 mi
A Phase 3 Study of Tabelecleucel for Participants With Epstein-Barr Virus-Associated Post-Transplant Lymphoproliferative Disease After Failure With Rituximab or Rituximab and ChemotherapyPhase 3<1 mi
LOTUS-CC: An Observational Research Study to Uncover Subtypes of Cancer Cachexia—<1 mi
Radiation Prior to TKI to Delay Progression in Advanced Driver-Mutated Non-small Cell Lung Cancers (RadiaNCe Lung X)Phase 2<1 mi
Clinical Validation of Freenome Multiomics Blood Test for Lung Cancer Screening—<1 mi
Testing the Addition of Radiation Therapy to the Usual Immune Therapy Treatment (Atezolizumab) for Extensive Stage Small Cell Lung Cancer, The RAPTOR TrialPhase 2/3<1 mi
Chemotherapy Combined With Immunotherapy Versus Immunotherapy Alone for Older Adults With Stage IIIB-IV Lung Cancer, The ACHIEVE TrialPhase 3<1 mi
Phase 1 Study to Investigate TCRTs KRAS Mutation in Unresectable, Advanced, and/or Metastatic Solid TumorsPhase 1<1 mi
Phase 1 Study of MRTX1719 in Solid Tumors With MTAP DeletionPhase 1<1 mi
A Study of NT-175 in Adult Participants With Advanced Malignancies That Are Positive for HLA-A*02:01 and the TP53 R175H MutationPhase 1<1 mi
Lung-MAP: A Master Screening Protocol for Previously-Treated Non-Small Cell Lung CancerPhase 2/3<1 mi
Assessing Benefits and Harms of Cannabis/Cannabinoid Use Among Cancer Patients Treated in Community Oncology Clinics—<1 mi
Dosing Physical Activity Among Older Cancer Survivors Who Experience Chronic Pain: a Micro-randomized TrialN/A<1 mi
Trial of Nab-sirolimus in Patients With Well-differentiated Neuroendocrine Tumors (NETs) of the Gastrointestinal Tract, Lung, or Pancreas Who Have Not Received Prior Treatment With mTOR InhibitorsPhase 2<1 mi
The MOMENTUM Study: The Multiple Outcome Evaluation of Radiation Therapy Using the MR-Linac Study—<1 mi
Evaluate the Clinical Performance of the Flow Cytometry - FlowPath Lung Test as a Sensitive and Specific Non-invasive Diagnostic of Sputum Samples to Identify/Detect the Presence of Lung Cancer in High-risk Individuals Who Have Existing Lung Nodules, 6 to <30 mm in Diameter, Determined by LDCT.N/A<1 mi
Study of INBRX-106 and INBRX-106 in Combination With Pembrolizumab (Keytruda®) in Subjects With Locally Advanced or Metastatic Solid Tumors (Hexavalent OX40 Agonist)Phase 1/2<1 mi
Immunotherapy After Surgery for People Who Have No Remaining Cancer Cells After Standard Treatment for Early-Stage Non-Small Cell Lung Cancer, INSIGHT TrialPhase 317 mi
An Open-label, Single-arm Study of Prophylaxis for Datopotamab Deruxtecan (Dato-DXd) -Related Stomatitis in Eligible Patients With Metastatic or Inoperable Locally Recurrent Breast Cancer or Locally Advanced or Metastatic Epidermal Growth Factor Receptor-Mutated Non-small Cell Lung Cancer.Phase 417 mi
Unhide® Project: A Digital Health Platform to Collect Lifestyle Data for Brain Inflammation Research—25 mi
A Phase 1 Study of BGB-B2033, Alone or in Combination With Tislelizumab With or Without Bevacizumab, in Participants With Advanced or Metastatic Solid TumorsPhase 141 mi
A Study of Amivantamab in Combination With Lazertinib, or Amivantamab in Combination With Platinum-Based Chemotherapy, for Common Epidermal Growth Factor Receptor (EGFR)-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)Phase 241 mi
LUNAR-2: TTFields With Pembrolizumab + Platinum-based Chemotherapy for Metastatic NSCLCPhase 341 mi
A Study Evaluating the Efficacy and Safety of Divarasib and Pembrolizumab Versus Pembrolizumab and Pemetrexed and Carboplatin or Cisplatin in Participants With Previously Untreated, KRAS G12C-Mutated, Advanced or Metastatic Non-Squamous Non-Small Cell Lung CancerPhase 341 mi
Phase III Study of Datopotamab Deruxtecan Versus Docetaxel in Previously Treated TROP2-positive Advanced or Metastatic Non-squamous NSCLC Without Actionable Genomic AlterationsPhase 341 mi
Immunotherapy Biomarkers to Predict First-line PD(L)1-based Immunotherapy Response and Selection of Second-line Treatment in Stage IIIB-IV Non-small Cell Lung Cancer, IMMUNO-BIOMAP TrialPhase 241 mi
Study of Tarlatamab + ZL-1310 +/- Anti-programmed Death Ligand 1 (Anti-PD-L1) in Small Cell Lung Cancer (SCLC)Phase 141 mi
A Study to Evaluate Adverse Events and Change in Disease Activity of Intravenous ABBV-706 Versus Standard of Care in Adult Participants With Relapsed/Refractory Small Cell Lung CancerPhase 341 mi
Targeted Treatment for Advanced Non-Small Cell Lung Cancer That Has a MET Exon 14 Skipping Gene Change (An Expanded Lung-MAP Treatment Trial)Phase 249 mi
Using Biomarker Tests to Select and Test New, Personalized Treatments for Extensive Stage Small Cell Lung Cancer, PRISM StudyPhase 249 mi
Radiotherapy to Block Oligoprogression In Metastatic Non-Small-Cell Lung CancerPhase 349 mi

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.